Clinical Trial: JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan

U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07384377) titled 'JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan' on Jan. 26.

Brief Summary: The study is being conducted to evaluate the efficacy and safety of JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan subjects.

Study Start Date: Feb. 06

Study Type: INTERVENTIONAL

Condition: HER2-positive Colorectal Cancer

Intervention: DRUG: JSKN003

JSKN003 (6.3 mg/kg) was administered intravenously on the first day ...